A unique collection of 140 compounds targeting MAPK signaling for drug discovery in MAPK related diseases; Bioactivity and safety confirmed by pre-clinical research and clinical trials, and some of them are approved by FDA; Targets include ERK, JNK, MEK, p38, MAPK, Raf, RSK, MNK, etc; Detailed compound information with structure, target, activity, IC50 value, and biological activity description; Structurally diverse, medicinally active, and cell permeable; NMR and HPLC validated to ensure high purity and quality
